44th week of 2010 patent applcation highlights part 48 |
Patent application number | Title | Published |
20100280046 | Methods and Compositions for Treating Prostate Cancer, Benign Prostatic Hypertrophy, Polycystic Ovary Syndrome and Other Conditions - Pharmaceutical compositions comprising the 2S,4R ketoconazole enantiomer or its pharmaceutically acceptable salts, hydrates, and solvates, that are substantially free of the 2R,4S ketoconazole enantiomer are useful to reduce testosterone synthesis and for the treatment of prostate cancer, benign prostatic hyperplasia, seborrhea, hirsutism, alopecia, polycystic ovary syndrome, and other diseases and conditions, including but not limited to systemic hyperandrogenism. | 2010-11-04 |
20100280047 | SALTS OF ACTIVE INGREDIENTS WITH POLYMERIC COUNTER-IONS - Polymeric water-soluble salts of medicaments that are sparingly soluble in water, consisting of a polymer with anion character that is soluble in water at pH values of 2-13 and a sparingly soluble medicament with cation character. | 2010-11-04 |
20100280048 | Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase - The invention provides certain novel 6-heteroaryl-5-methyl-3-oxo-4-[3(trifluoromethyl)phenyl]-3,4-dihydropyrazine-2-carboxamide derivatives and pharmaceutically acceptable salts thereof and particular Forms thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase. | 2010-11-04 |
20100280049 | ANTAGONISTS OF PGD2 RECEPTORS - Described herein are compounds and pharmaceutical compositions containing such compounds that antagonize the PGD2 activated chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2). Also described herein are methods of using such CRTH2 antagonists, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2 mediated conditions or diseases. | 2010-11-04 |
20100280050 | Piperidinylamino-Thieno[2,3-D] Pyrimidine Compounds for Treating Fibrosis - The invention provides a method of treating or preventing fibrosis in a subject by administering a 5-HT modulator, e.g., a 5-HT | 2010-11-04 |
20100280051 | USE OF ALLOPURINOL FOR THE TREATMENT OF HAND FOOT SKIN REACTION - Use of allopurinol or a pharmaceutically acceptable salt thereof for the treatment or prevention of Hand Foot Skin Reaction (HFSR) induced by Multitargeted Kinase Inhibitor (MKI) therapy. The allopurinol or its salt is administered topically to the affected areas, palms and soles, preferably in the form of a cream. | 2010-11-04 |
20100280052 | USE OF ANTIVIRALS TO TREAT CMV-RELATED CONDITIONS - The invention provides for the use of compounds active against cytomegalovirus (CMV) in the preparation of medicaments for improving the immune response of a CMV-seropositive, immunocompetent individual, or for the amelioration of certain other medical conditions. Suitable compounds include the nucleoside analogues acyclovir, famciclovir, and valacyclovir. Infection with cytomegalovirus is widespread and commonly believed to be both asymptomatic in immunocompetent individuals and unbeatable without the use of highly cytotoxic drugs. It is suggested herein that, in fact, CMV infection produces a disproportionately large immune response, thereby weakening the ability of the immune system to respond to other infections (and hence is not asymptomatic). Further, treatment with comparatively low doses of drugs having low cytotoxicity (and hence similarly low efficacy) can reduce the magnitude of this CMV-specific immune response, improving the overall immune response, and ameliorating the symptoms of other medical conditions. | 2010-11-04 |
20100280053 | CyclopropylmethYl-[7-(5,7-dimethyl-benzo[1,2,5]thiodiazol-4-yl)-2,5,6-trim- ethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-4-propyl-amine as a CRF Antagonist - The present invention relates to a novel benzothiadiazole of formula (A) in free base or acid addition salt form, its preparation, its use as pharmaceutical and pharmaceutical compositions containing the compound. | 2010-11-04 |
20100280054 | MULTICYCLIC AMINO ACID DERIVATIVES AND METHODS OF THEIR USE - Compounds of formulae I and II are disclosed, as well as compositions comprising them and methods of their use to treat, prevent and manage serotonin-mediated diseases and disorders: | 2010-11-04 |
20100280055 | Flavoring Systems for Pharmaceutical Compositions and Methods of Making Such Compositions - A flavoring system for a liquid pharmaceutical composition and pharmaceutical compositions containing such flavoring systems are disclosed. Flavoring systems of the invention include at least one sweetening agent, at least two flavored ingredients, and at least one flavor modifier selected from the group consisting of citric acid, sodium citrate, sodium chloride, and mixtures thereof. At least two of the flavored ingredients are selected from the group consisting of a vanilla flavored ingredient, a peppermint flavored ingredient, a menthol flavored ingredient, a cotton candy flavored ingredient, and mixtures thereof. The one or more sweetening agents comprise glycerin, monoammonium glycyrrhizinate, saccharin sodium, acesulfame potassium, high fructose corn syrup, and/or mixtures thereof. Pharmaceutical compositions of the invention include a flavoring system of the invention, a solvent system, and at least one pharmaceutically active agent, such as lopinavir or derivatives thereof, ritonavir or derivatives thereof, or mixtures thereof. Methods for making such liquid pharmaceutical compositions are also disclosed. | 2010-11-04 |
20100280056 | IDENTIFICATION OF SUBJECTS LIKELY TO BENEFIT FROM STATIN THERAPY - Methods are provided herein to determine if a subject is a candidate for treatment with an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR). The method includes determining the presence of at least one polymorphism in the HMGCR gene in a sample from a subject. The presence of at least one polymorphism indicates that the subject is a candidate for treatment with a statin, for example to decrease risk of or treat cancer, cardiovascular disease, diabetes, obesity, inflammatory disease, or auto-immune disease. | 2010-11-04 |
20100280057 | NOVEL ANALGESIC THAT BINDS FILAMIN A - A compound, composition and method are disclosed that can provide analgesia. A contemplated compound has a structure that corresponds to Formula I, wherein R | 2010-11-04 |
20100280058 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE - Spirocyclic heterocyclic derivatives, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the spirocyclic heterocyclic derivatives are ligands of the δ opioid receptor and may be useful, inter alia, for treating and/or preventing pain, anxiety, gastrointestinal disorders, and other δ opioid receptor-mediated conditions. | 2010-11-04 |
20100280059 | COMPOSITIONS COMPRISING AN ANTIHISTAMINE, ANTITUSSIVE AND DECONGESTANT IN EXTENDED RELEASE FORMULATIONS - The invention provides oral formulations for the treatment of cold and allergy symptoms. Each formulation combines an antihistamine, an antitussive, and/or a decongestant into one extended release composition. The invention further provides for methods of making and using such formulations, as well as for methods for preventing abuse or extraction of a single drug present in an oral extended release composition comprising two or more of an antihistamine, antitussive, and/or decongestant. | 2010-11-04 |
20100280060 | Methods of screening and compositions for life span modulators - Identification of nucleic acids involved in life span diseases and disorders or related diseases and disorders, and the use of such methods for identifying candidate agents which modulate life span diseases and disorders or related diseases and disorders are provided. Compositions and methods for treating life span diseases and disorders or related diseases and disorders are provided. Pharmaceutical compositions for treating life span diseases and disorders or related diseases and disorders are also provided | 2010-11-04 |
20100280061 | NOVEL ANALGESIC THAT BINDS FILAMIN A - A compound, composition and method are disclosed that can bind to FLNA and provide analgesia. A contemplated compound has a structure that corresponds to Formula I, wherein R | 2010-11-04 |
20100280062 | (E)-N--METHANESULFONAMIDE AS GLUCOCORTICOID RECEPTOR MODULATOR FOR THE TREATMENT OF RHEUMATOID ARTHRITIS - The present invention provides Compound (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising Compound (I) in combination with one or more pharmaceutically acceptable carriers, excipients, or diluents; and discloses methods for the treatment of inflammatory and immune disorders comprising administering to a patient in need thereof an effective amount of Compound (I) or a pharmaceutically acceptable salt thereof. | 2010-11-04 |
20100280063 | 8-ANILINOIMIDAZOPYRIDINES AND THEIR USE AS ANTI-CANCER AND/OR ANTI-INFLAMMATORY AGENTS - The invention relates to imidazopyridines of formula I with anti-cancer and/or anti-inflammatory activity and more specifically to imidazopyridines which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions. | 2010-11-04 |
20100280064 | PHARMACEUTICAL COMPOSITION HAVING IMPROVED STORAGE STABILITY - A pharmaceutical composition containing (A) a compound represented by the formula (I) below or a pharmacologically acceptable salt thereof, and (B) a water-soluble polymer. The formula (I) is as follows: | 2010-11-04 |
20100280065 | PERHARIDINES AS CDK INHIBITORS - The invention relates to trisubstituted or tetrasubstituted imidazo[4,5b]pyridines, to their uses as well as to a process for manufacturing them. | 2010-11-04 |
20100280066 | ACYLATED AMINO ACID AMIDYL PYRAZOLES AND RELATED COMPOUNDS - This invention is directed to acylated amino acid amidyl pyrazoles and related compounds of Formula I. The invention is also directed to a pharmaceutical formation comprising such compound or in a pharmaceutically acceptable salt form thereof. The invention is further directed to a method for inhibiting β-amyloid peptide release and/or synthesis, a method for inhibiting γ-secretase activity, and a method for treating neurological disorders associated with β-amyloid peptide production. The method comprises administering to a host a pharmaceutical formulation comprising an effective amount of a compound of Formula I. The compounds of Formula I are useful in the prevention and treatment of Alzheimer's disease. | 2010-11-04 |
20100280067 | INHIBITORS OF ACETYL-COA CARBOXYLASE - The present invention relates to compounds that act as acetyl-CoA carboxylase (ACC) inhibitors. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds. | 2010-11-04 |
20100280068 | QUINOLINE DERIVATIVES AND THEIR USE AS FUNGICIDES - Compounds of the general Formula (1) wherein the substituents are as defined in claim | 2010-11-04 |
20100280069 | CONTROLLED RELEASE LOCAL ANESTHETIC FOR POST DENTAL SURGERY AND METHOD OF USE - The present invention relates to a method of delivering local anesthetic after dental extraction surgery. The present invention relates to packing the tooth socket with a tinned release local anesthetic which is coordinated with an initial local anesthetic and which lasts up to 5 days. The socket can be surgically sealed or the implant can act as the sealing means. | 2010-11-04 |
20100280070 | NOVEL TETRAHYDROQUINOLINES AS AROMATASE INHIBITORS - The invention relates to synthesis and biological screening of novel tetrahydroquinolines of formula (I), their derivatives, their stereoisomers, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them for aromatase inhibition: (I). The present invention also relates to a process for the preparation of the novel tetrahydroquinolines, their derivatives, their stereoisomers, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them. These compounds are useful in for aromatase inhibition, particularly in the treatment and/or prevention of cancer, particularly breast cancer, more particularly hormone dependent breast cancer. | 2010-11-04 |
20100280071 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE - Compounds of formula (I), salts and solvates are provided: | 2010-11-04 |
20100280072 | 2-'4-(HYDROXYMETHYL-PHENYLAMINO) -PIPERIDINE-1-YL!-N- (9H-CARBAZOL-3YL) - ACETAMINE DERIVATIVES AND RELATED COMPOUNDS AS NEUROPEPTIDE Y5 (NPY5) LIGANDS FOR THE TREATMENT OF OBESITY - The present invention relates to 1,4-disubstituted piperidine compounds of general formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans or animals. The substituents are as defined in the present claim | 2010-11-04 |
20100280073 | TRICYCLIC INHIBITORS OF HYDROXYSTEROID DEHYDROGENASES - The present invention provides tricyclic compounds according to formula (I): (I) where R | 2010-11-04 |
20100280074 | CCR9 INHIBITORS AND METHODS OF USE THEREOF - The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods. | 2010-11-04 |
20100280075 | PACLITAXEL ENHANCER COMPOUNDS - Disclosed is a compound represented by the Structural Formula (I): | 2010-11-04 |
20100280076 | DERIVATIVES OF DIOXAN-2-ALKYL CARBAMATES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPEUTICS - A compound corresponding to general formula (I): | 2010-11-04 |
20100280077 | Process for Preparation of Stable Amorphous R-Lansoprazole - A process for preparing stable amorphous R-(+)-lansoprazole comprising optically resolving racemic lansoprazole by the formation of host-guest inclusion complexes by selectively and reversibly including chiral guest molecules in the lansoprazole. | 2010-11-04 |
20100280078 | 1-(Azolin-2-yl)amino-1,2-diphenylethane compounds for combating animal pests - The present invention relates to 1-(azolin-2-yl)amino-1,2-diphenylethane compounds of the formula I and to their salts which are useful for combating animal pests. The invention also relates to a method for controlling animal pests by using these compounds, to seed and to an agricultural and veterinary composition comprising said compounds. | 2010-11-04 |
20100280079 | 0NOVEL, 1,2,4-THIADIAZOLIUM DERIVATIVES AS MELANOCORTIN RECEPTOR MODULATORS - The present invention is directed to novel 1,2,4-thiadiazol-2-ium derivatives useful as agonists or antagonists of the melanocortin receptor. More particularly, the compounds of the present invention are useful for the treatment of metabolic, CNS and dermatological disorders such as obesity, impaired oral glucose tolerance, elevated blood glucose levels, type II diabetes, Syndrome X, diabetic retinopathy, spinal cord injury, nerve injury, acute neurodegenerative disorders, chronic neurodegenerative disorders, plexopathies, male erectile dysfunction, dry eyes, acne, dry skin, aged skin, seborrheic dermatitis, rosacea, excessive ear wax, meibomian gland disorder, pseudofolliculitis, yeast infections, dandruff, hidradenitis suppurativa, ocular rosacea and eccrine gland disorder. | 2010-11-04 |
20100280080 | Medicaments - Methods of prevention or treatment of renal diseases or conditions associated with abnormal ion flux, in particular autosomal dominant polycystic kidney disease, with a modulator of human peroxisome proliferator activated receptor gamma. | 2010-11-04 |
20100280081 | ANTI-INFLAMMATORY AGENTS AS VIROSTATIC COMPOUNDS - The present invention relates to compounds of the general formula (I) and salts and physiologically functional derivatives thereof, | 2010-11-04 |
20100280082 | Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators - Compounds of Formula (I) wherein R | 2010-11-04 |
20100280083 | NOVEL CATECHOL DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, USE OF THE CATECHOL DERIVATIVE, AND USE OF THE PHARMACEUTICAL COMPOSITION - The present invention provides compounds represented by general formula (I): | 2010-11-04 |
20100280084 | Cyp1B1 Genotype - The invention relates to pharmacology, pharmacokinetics and toxicology, and more specifically to methods of identifying and predicting inter-patient differences in response to drugs in order to achieve superior efficacy and safety in selected patient populations. It further related to the genetic basis of inter-patient variation in response to therapy, including drug therapy, and to methods for determining and exploiting such differences to improve medical outcomes. | 2010-11-04 |
20100280085 | CHEMICAL COMPOUNDS - The use of a compound of formula (I) wherein X is (i), (ii) or (iii), where the substituents have the meanings assigned to them in claim | 2010-11-04 |
20100280086 | SUBSTITUTED THIOPHENES - Disclosed herein are substituted pyrimidine-based endothelin modulators of Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof. | 2010-11-04 |
20100280087 | NOVEL 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS - This invention relates to novel 2-amino benzimidazole derivatives useful as modulators of small-conductance calcium-activated potassium channels (SK channels). In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention. | 2010-11-04 |
20100280088 | HALOSUBSTITUTED ARYLOXYALKYLIMIDAZOLINES FOR USE AS PESTICIDES - The present invention relates to novel imidazoline derivatives and their use as insecticidal, acaricidal, molluscicidal and nematocidal agents. The invention also extends to insecticidal, acaricidal, molluscicidal and nematicidal compositions comprising such imidazoline derivatives, and to methods of using such derivatives and/or compositions to combat and control insect, acarine, mollusc and nematode pests. A compound of formula (I) and salts and N-oxides thereof, wherein: R | 2010-11-04 |
20100280089 | USE OF INHIBITORS OF JUN N-TERMINAL KINASES FOR THE TREATMENT OF GLAUCOMATOUS RETINOPATHY AND OCULAR DISEASES - Compositions and methods for the treatment of glaucoma and other ocular diseases are disclosed. The compositions and methods are particularly directed to the use inhibitors of Jun N-terminal kinases (JNK), such as SP600125 in the treatment of glaucoma and other ocular diseases. | 2010-11-04 |
20100280090 | TAPE PREPARATION COMPRISING ETODOLAC IN IONIC LIQUID FORM - Disclosed is a tape preparation comprising etodolac in an ionic liquid form, which has high transdermal absorbability. Etodolac is reacted with an organic amine compound to produce an ionic liquid of etodolac. By using the ionic liquid, it becomes possible to increase the transdermal absorbability of etodolac. Further for the purpose of enhancing the transdermal absorbability and the tissue penetration ability of an ionic solution of etodolac, the composition of an organic solvent system for the ionic solution of etodolac is investigated, and it is found that a mixed solvent of an alcohol and an ester (1:2 to 2:1) is suitable as the organic solvent. Still further, an appropriate adhesion force can be achieved by properly selecting a softening agent. In this manner, a tape preparation having good transdermal absorbability can be prepared. The tape preparation can exert its pharmacological efficacy rapidly, and is therefore extremely effective for the teatment of a chronic pain such as rheumatoid arthritis, osteoarthritis and lumbago, an inflammatory diseases such as shoulder periarthritis and tendovaginitis, cervical syndrome, a pain induced by a surgery or an injury, or the like. | 2010-11-04 |
20100280091 | TRI-SUBSTITUTED 2-BENZHYDRYL-5-BENZYLAMINO-TETRAHYDRO-PYRAN-4-OL AND 6-BENZHYDRYL-4-BENZYLAMINO-TETRAHYDRO-PYRAN-3-OL ANALOGUES, AND NOVEL 3,6-DISBUSTITUTED PYRAN DERIVATIVES - Novel 3,6-disubstituted pyrans, optionally with a further substituent at the 4-position, are monoamine reuptake inhibitors with activity profiles of anti-depressants. | 2010-11-04 |
20100280092 | N-ACYLHYDRAZONE DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS - This invention relates to N-acylhydrazone derivatives, which are found to be useful as modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances. | 2010-11-04 |
20100280093 | PROCESS FOR THE PREPARATION ENANTIOMERICALLY PURE SALTS OF N-METHYL-3-(1-NAPHTHALENEOXY)-3-(2-THIENYL)PROPANAMINE - The present invention relates to duloxetine salts having enantiomeric purity of 98% or more and a process for such salts. | 2010-11-04 |
20100280094 | COMPOSITIONS AND METHODS TO TREAT MUSCULAR & CARDIOVASCULAR DISORDERS - The present invention relates to a novel microRNA, mir-208-2, implicated in muscular and cardiovascular disorders. The present invention also relates to oligonucleotide therapeutic agents (antisense oligonucleotides and/or double stranded oligonucleotides such as dsRNA) and their use in the treatment of muscular and cardiovascular disorders resulting from dysregulation of mir-208-2. | 2010-11-04 |
20100280095 | THERAPEUTIC AGENT FOR WOUNDS AND SCREENING METHOD FOR THE SAME - The present invention provides an agent for treating wound, containing a substance that suppresses the expression or function of PDLIM2. The substance that suppresses the expression or function of PDLIM2 is preferably an siRNA or antisense nucleic acid capable of specifically suppressing the expression of PDLIM2, or an expression vector capable of expressing said polynucleotide. In addition, the present invention provides a method of screening for a substance capable of treating wounds, including determining whether or not a test substance is capable of suppressing the expression or function of PDLIM2. | 2010-11-04 |
20100280096 | TREATMENT OF INFLUENZA - The present invention provides a double-stranded RNA which inhibits replication of influenza B viruses by RNA interference, in which the double-stranded RNA comprises an RNA having 19 to 25 nucleotides homologous with a part of an mRNA transcribed from a genomic RNA of the influenza B viruses and an antisense RNA thereof. | 2010-11-04 |
20100280097 | COMPOSITIONS COMPRISING HIF-1 ALPHA SIRNA AND METHODS OF USE THEREOF - The present invention provides nucleic acid molecules that inhibit HIF-1α expression. Methods of using the nucleic acid molecules are also provided. | 2010-11-04 |
20100280098 | RECEPTOR TARGETED OLIGONUCLEOTIDES - Disclosed herein are oligonucleotide conjugates that include ligands that target cell receptors that mediate endocytosis. The ligands can include peptides and small molecules. The conjugates can include carrier macromolecules to which the ligands and oligonucleotides are attached, or conjugates where an oligonucleotide is attached to a ligand in the absence of a carrier macromolecule. The oligonucleotides can include therapeutic oligonucleotides, such as siRNA, antisense RNA and miRNA. The ligand can be an RGD peptide. Also disclosed herein are methods of delivering the conjugates to cells in subjects. | 2010-11-04 |
20100280099 | Combination Treatment For The Treatment of Hepatitis C Virus Infection - The present invention relate to the use of a combination of an inhibitor of miR-122 and an inhibitor of VLDL assembly, for the treatment of HCV, hyperlipidemia and hypercholesterolemia. | 2010-11-04 |
20100280100 | TREATMENT OF HEMOGLOBIN (HBF/HBG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO HBF/HBG - The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Hemoglobin (HBF/HBG), in particular, by targeting natural antisense polynucleotides of Hemoglobin (HBF/HBG). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of HBF/HBG. | 2010-11-04 |
20100280101 | METHOD OF INHIBITING CANCER CELL PROLIFERATION, PROLIFERATION INHIBITOR AND SCREENING METHOD - The present invention provides a method of inhibiting cancer cell proliferation by suppressing a function of ZNF143, a cancer cell proliferation inhibitor containing as an active ingredient a substance capable of inhibiting a function of ZNF143, like a ZNF143-specific siRNA, a prophylactic and/or therapeutic drug for cancer, a method of detecting cancer cells, a diagnostic reagent for cancer, a vector and transformant cell incorporating the vector, and a screening method for a substance possessing cancer cell proliferation inhibitory activity with the amount of inhibition of the binding of ZNF143 protein as an index. | 2010-11-04 |
20100280102 | DOUBLE-STRANDED RIBONUCLEIC ACID WITH INCREASED EFFECTIVENESS IN AN ORGANISM - The present invention relates to a method for the targeted selection of a double-stranded ribonucleic acid (dsRNA) consisting of two single strands that exhibits increased effectiveness in inhibiting the expression of a target gene by means of RNA interference, wherein at least end of the dsRNA comprises a nucleotide overhang of 1 to 4 unpaired nucleotides in length; wherein the unpaired nucleotide adjacent to the terminal nucleotide pair comprises a purine base; and wherein the terminal nucleotide pair on both ends of the dsRNA is a G-C pair, or at least two of the last four consecutive terminal nucleotide pairs are G-C pairs. | 2010-11-04 |
20100280103 | Methods and compositions for acid phosphatase-1 gene inhibition - The ACP1 *A allele provides a means for diagnosing susceptibility of a human subject to hyperlipidemia, especially hyperlipidemia associated with metabolic syndrome, a means for treating, or preventing the onset of, hyperlipidemia and metabolic syndrome, and a means for screening and identifying drugs suitable for use in treating or preventing hyperlipidemia, especially hyperlipidemia associated with metabolic syndrome. Diagnostic kits are also provided. | 2010-11-04 |
20100280104 | METHODS AND KITS FOR DIAGNOSIS AND TREATMENT OF CELL-CELL JUNCTION RELATED DISORDERS - We have discovered that loss of Filamin A function results in weakened cell-cell junctions and vascular defects in genetically engineered mice. In addition, we have shown that patients with mutations in the gene coding for Filamin A exhibit high rates of cardiovascular disorders. On the basis of this discovery, the present invention features methods and kits for diagnosis of cell-cell junction related disorders (e.g., atherosclerosis, aortic aneurysm, or any disease described herein), as well as screening methods | 2010-11-04 |
20100280105 | DETECTION OF MAGE-A EXPRESSION - An oligonucleotide, primer or probe comprises the nucleotide sequences of any of SEQ ID NO. 5, 6, 7, 2, 3, 4, 8, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 25. The oligonucleotides are useful for the detection of the methylation status of a gene, in particular the MAGE-A3 gene. The oligonucleotides are useful in primer pairs, kits and methods for determining the methylation status of the MAGE-A3 gene and for diagnosing cancer, directing therapy and selecting subjects for treatment. The primer or probe can comprise a loop or hairpin structure and can be used in real-time methylation specific PCR. | 2010-11-04 |
20100280106 | ORAL COMPOSITION TO REDUCE COLD SYMPTOMS AND DURATION OF SAME - An oral spray composition for preventing and/or reducing the symptoms of the common cold including a zinc formulation containing both zinc acetate and zinc gluconate to ensure sustained availability of increased amounts of ionizable zinc. | 2010-11-04 |
20100280107 | TREATING BENIGN PROSTATE HYPERPLASIA WITH SARMS - This invention provides a method of treating, preventing, suppressing, inhibiting or reducing the incidence of benign prostate hyperplasia in a male subject, by administering to the subject a selective androgen receptor modulator (SARM) and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof as described herein. This invention also provides a method of treating a subject suffering from hair loss, comprising the step of administering to the subject a therapeutically effective amount of a 5-α reductase enzyme type 1 and/or type 2 inhibitor, wherein said inhibitor is a selective androgen receptor modulator (SARM) and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof as described herein. This invention also provides a method of inhibiting a 5-α reductase type 1 and/or type 2 enzyme, comprising contacting the enzyme with an effective 5-α reductase inhibitory amount of a selective androgen receptor modulator (SARM) and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof, as described herein. | 2010-11-04 |
20100280108 | Antitumoral Compounds - A compound of general formula (I) | 2010-11-04 |
20100280109 | LIPID COMPOUNDS FOR USE IN COSMETIC PRODUCTS, AS FOOD SUPPLEMENT OR AS A MEDICAMENT - The present disclosure relates to lipid compounds of formula (I): | 2010-11-04 |
20100280110 | (3R)-L-MENTHYL 3-HYDROXYBUTYRATE, PROCESS FOR PRODUCING THE SAME, AND SENSATE COMPOSITION COMPRISING THE SAME - The present invention provides a cooling component or sensate component which has further strong cooling intensity and is excellent in the persistency or refresh-feeling and cool-feeling, a sensate composition comprising the same, and various products comprising the sensate composition. The present invention relates to, as a cooling component or sensate component, (3R)-1-menthyl 3-hydroxybutyrate represented by the following formula (I): | 2010-11-04 |
20100280111 | SKIN EXTERNAL PREPARATIONS AND COSMETICS - An object of the present invention is to provide skin external preparations and cosmetics which contain a branched acyl carnitine and have excellent formulation stability. A skin external preparation of the present invention includes a carnitine derivative represented by the following Formula (1) and/or a carnitine derivative salt represented by the following Formula (2), and an amphoteric surfactant. | 2010-11-04 |
20100280112 | Composition Enriched in Diglyceride with Conjugated Linoleic Acid - The present invention relates to an oil composition containing a large amount of a. diglyceride of conjugated linoleic acid (CLA), and more particularly to an oil composition with body weight control, anticancer, antioxidation and immune enhancement functions, which is based on a diglyceride of conjugated linoleic acid resulted from an enzymatic reaction between conjugated linoleic acid obtained from edible oil and glycerol. The inventive oil composition comprises 40-95% by weight of diglycerides, 5-60% by weight of triglycerides, 0.110% by weight of monoglycerides, and 0.02-10% by weight of residues, in which the ratio of conjugated linoleic acid (CLA) to fatty acids contained in the total glycerides is 5-98%. The use of the oil composition provides high-added-value foods, pharmaceutical compositions and foodstuff additives with effects of anticancer, immune enhancement, antioxidation, antichlorestol, growth promotion and the like. | 2010-11-04 |
20100280113 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS - The invention is directed to novel pharmaceutical compositions comprising chemicals agents that are useful in the treatment and prevention of cystic fibrosis and the prevention of signs and symptoms of this disease. These pharmaceutical compositions are surprisingly successful in the treatment disorders related to cystic fibrosis including disorders of blood production. Many of these compositions of the invention are even more effective when administered to a patient in pulses. Pulse therapy is not a form of discontinuous administration of the same amount of a composition over time, but comprises administration of the same dose of the composition at a reduced frequency or administration of reduced doses. | 2010-11-04 |
20100280114 | Primers and primer sets for use in methods to detect the presence of acidovorax avenae subsp. citrulli - The present invention relates to oligonucleotide primers and primer sets that can be used to identify the bacterial pathogen | 2010-11-04 |
20100280115 | COMPOSITIONS OF HUMAN LIPIDS AND METHODS OF MAKING AND USING SAME - The disclosure features methods of making compositions that include a human lipid. The methods can include: obtaining whole human milk; separating the milk into a cream portion and a skim portion; processing the cream portion; and pasteurizing the processed cream portion. | 2010-11-04 |
20100280116 | LINOLEIC ACID ACTIVE AGENTS FOR ENHANCING PROBABILITY OF BECOMING PREGNANT - The present invention is directed to a methods and compositions for enhancing the probability that a subject will become pregnant. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a linoleic acid active agent, e.g., linoleic acid, a polyunsaturated fatty acid analog thereof, etc. Also provided are kits that find use in practicing the subject methods. The subject methods and compositions find use in a variety of different applications, including but not limited to the treatment of infertility conditions. | 2010-11-04 |
20100280117 | Menorrhagia Instrument and Method for the Treatment of Menstrual Bleeding Disorders - Disclosed is a Menorrhagia Instrument and methods for the treatment of menstrual bleeding disorders. | 2010-11-04 |
20100280118 | Methods for treating substance dependence - The present invention provides methods for treating alcohol dependence and preventing relapse in subjects in protracted alcohol abstinence. Also provided are methods for treating subjects suffering from cannabis dependence. Typically, these methods entail administering to the subjects in need of treatment a therapeutically effective amount of gabapentin, an analog of gabapentin, or pharmaceutically acceptable salt thereof. | 2010-11-04 |
20100280119 | L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF - Disclosed herein are crystalline forms of L-ornithine phenyl acetate and methods of making the same. The crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate. | 2010-11-04 |
20100280120 | COMPOUND INDUCING ANGIOGENESIS RESPONSE IN ISCHAEMIC TISSUES - This invention deals with a novel straight chain compound, namely, 1,6-diamino alkanoic acid having a straight chain of six carbon atoms with two terminal amino groups and accompanying —COOH group, which is capable of effecting controlled formation of new blood vessels in ischaemic tissues, and their pharmaceutically acceptable salts and/or derivatives thereof. The compounds may be in laevo, dextro, activated laevo, activated dextro or oligomeric form. The invention also pertains to a process for preparing the aforesaid novel compound, which is illustrated by the accompanying drawing. | 2010-11-04 |
20100280121 | PRODUCTION OF ADAPALENE GELS - A method for producing an adapalene aqueous gel on an industrial scale including formulating a gelling medium A by mixing water and propylene glycol and adding a gelling agent thereto; formulating an adapalene medium B by dispersing adapalene in water, in the presence of a surfactant; next adding the adapalene medium B to the gelling medium A; and adjusting the pH to about 4.7-5.3. | 2010-11-04 |
20100280122 | TRANSDERMAL DELIVERY OF BENEFICIAL SUBSTANCES EFFECTED BY A HOSTILE BIOPHYSICAL ENVIRONMENT - The present invention generally relates to the transdermal delivery of substances and, in some embodiments, to the transdermal delivery of beneficial substances by a hostile biophysical environment. In one aspect, various methods for the transdermal delivery of beneficial substances are disclosed. By creating a hostile biophysical environment, beneficial substances may be delivered, according to certain embodiments, through the stratum corneum of the skin into the body. Beneficial substances include, but are not limited to, pharmaceutical agents, drugs, vitamins, co-factors, peptides, dietary supplements, and others. The beneficial effects disclosed include, for instance, relief of pain and inflammation, prevention and healing of ulcers of the skin, relief of headache, improved sexual function and enjoyment, growth of hair on the scalp, improving muscle size and/or function, removing body fat and/or cellulite, treating cancer, treating viral infections and others. A hostile biophysical environment may also be used in conjunction with systems and methods for increasing local blood flow, according to one set of embodiments. For example, by using a nitric oxide donor such as L-arginine, local blood flow may be increased, e.g., by transdermally delivering the nitric oxide precursor. The nitric oxide donor may be the sole cause of increased blood flow, or it may be supplemented with an adjunct such as theophylline. | 2010-11-04 |
20100280123 | FOOD SUPPLEMENT CONTAINING ALPHA-KETO ACIDS FOR SUPPORTING DIABETES THERAPY - Food supplement containing alpha-keto acids for supporting diabetes therapy. The present invention relates to a formulation which is used as food supplement and contains alpha-keto acids for supporting therapy in diabetes mellitus type II (DM). | 2010-11-04 |
20100280124 | ACYL-UREA DERIVATIVES AND USES THEREOF - Novel acyl-urea containing compounds, processes of preparing same, compositions containing same and uses thereof in the treatment of neurological diseases and disorders such as epilepsy, neuropathic pain, bipolar disorder, status epilepticus, chemically-induced convulsions and/or seizure disorders, febrile convulsions conditions, metabolic disturbances and a sustenance withdrawal conditions, are provided. Also provided are uses of these and other acyl-urea containing compounds in the treatment of neurological diseases and disorders. | 2010-11-04 |
20100280125 | MEDICINAL AGENT - Medicine and pharmacology, in particular a medicinal agent exhibiting anti-tumoral and immunomodulatory actions and including a tri-p-amino-thiphenyl-chlormethan tetramethylated, pentamethylated or hexamethylated derivative, the mixtures thereof or the combination thereof with dextrin. The agent of this invention exhibits a high activity and a reduced side effect. | 2010-11-04 |
20100280126 | Method of Inhibiting Inflammatory Pain - A method of treating or inhibiting, in particular, pain caused by inflammation in a mammal by administering to the mammal an effective inflammatory pain alleviating amount of a (1R,2R)-3-(2-dimethylaminomethyl-cyclohexyl)-phenol compound or a physiologically acceptable salt thereof, such as the hydrochloride or citrate salt. | 2010-11-04 |
20100280127 | INHIBITING NEUROTRANSMITTER REUPTAKE - This document relates to compounds as well as methods and materials involved in modulating neurotransmitter reuptake. For example, compounds, methods for synthesizing compounds, and methods for inhibiting neurotransmitter reuptake are provided. | 2010-11-04 |
20100280128 | Use of 1-phenyl-3-dimethylaminopropane Compounds for Treating Rheumatoid Pain - The use of 1-phenyl-3-dimethylaminopropane compounds for the treatment of rheumatoid pain, especially rheumatoid arthritic pain, very especially preferably chronic rheumatoid arthritic pain. | 2010-11-04 |
20100280129 | Method of Treating Pain Caused by Inflammation - A method of treating or inhibiting, in particular, pain caused by inflammation in a mammal by administering to the mammal an effective inflammatory pain alleviating amoung of a (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol compound or a physiologally acceptable salt thereof, such as the hydrochloride or citrate salt. | 2010-11-04 |
20100280130 | QUINONE DERIVATIVE 2,3-DIMETHOXY-5-METHYL-6-(10-HYDROXYDECYL)-1,4-BENZOQUINONE FOR THE TREATMENT OF PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS - The present invention relates to approaches, methods, pharmaceuticals and uses directed to the curative treating or preventing of Primary Progressive Multiple Sclerosis (PP-MS), by using 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone (Idebenone) as the active agent. | 2010-11-04 |
20100280131 | METHODS FOR THE INHIBITION OF ATROPHY OR FOR TREATMENT OR PREVENTION OF ATROPHY-RELATED SYMPTOMS IN WOMEN - This invention relates to a method for inhibition of skin atrophy, or epithelial or mucosal atrophy in women, or to a method for treatment or prevention of symptoms related to said atrophy, said method comprising administering to the woman an effective amount of the compound of formula (I) | 2010-11-04 |
20100280132 | METHOD FOR MODIFYING POLYPHENOL CONTAINING PLANT MATERIALS AND MEDICAL USES OF MODIFIED POLYPHENOL PLANT CONTAINING MATERIALS - The present invention relates to a method for modifying polyphenol containing plant material(s), wherein said method comprises: mixing at least one polyphenol containing material and at least one solvent to provide a mixture; heating the mixture to eliminate bacterial species present to provide a heated mixture; adding at least one polyphenol modifying strain of lactic acid bacteria and optionally at least one protein source, in optional order or simultaneously, to the heated mixture to provide a fermentation mixture; and subjecting the fermentation mixture to conditions suitable for fermentation of the fermentation mixture to provide a mixture of modified polyphenol containing plant material(s); and optionally eliminating the polyphenol modifying strain of lactic acid bacteria to provide a mixture of modified polyphenol containing plant material(s) free from living lactic acid bacteria. | 2010-11-04 |
20100280133 | AQUEOUS EMULSION CONTAINING A CYCLODEXTRIN DERIVATIVE, A PERFUME, AND A POLYSORBATE - Aqueous fragrance emulsions are prepared from a hydrophobic fragrance substance, a cyclodextrin derivative, and a polysorbate. The emulsions are stable despite containing a high proportion of fragrance and can be used to prepare uniform coatings on substrates. | 2010-11-04 |
20100280134 | Markers for Bladder Cancer Detection - A method of detecting a predisposition to, or the incidence of, bladder cancer in a sample comprises detecting an epigenetic change in at least one gene selected from TWIST1, NID2, RUNX3, BMP7, CCNA1, PDLIM4, TNFRSF25, APC, RASSF1A, LOXL1, TUBB4, NTRK2, ARFGAP3, OSMR and TJP2. Detection of the epigenetic change is indicative of a predisposition to, or the incidence of, bladder cancer. The gene may be TWIST1 or a panel of genes such as TWIST1, NID2 and RUNX3 may be screened. The epigenetic change may be methylation. A kit for detecting a predisposition to, or the incidence of, bladder cancer in a sample comprises at least one primer pair for determining the methylation status of each of NID2, TWIST1 and RUNX3. A kit for detecting a predisposition to, or the incidence of, bladder cancer in a sample comprises means for detecting an epigenetic change in at least one gene selected from TWIST1, NID2, RUNX3, BMP7, CCNA1, PDLIM4, TNFRSF25, APC, RASSF1A, LOXL1, TUBB4, NTRK2, ARFGAP3, OSMR and TJP2. The kit also contains means for processing a urine sample. | 2010-11-04 |
20100280135 | Hydrocarbon and alcohol fuels from variable, renewable energy at very high efficiency - A Renewable Fischer Tropsch Synthesis (RFTS) process produces hydrocarbons and alcohol fuels from wind energy, waste CO2 and water. The process includes (A) electrolyzing water to generate hydrogen and oxygen, (B) generating syngas in a reverse water gas shift (RWGS) reactor, (C) driving the RWGS reaction to the right by condensing water from the RWGS products and separating CO using a CuAlCl4-aromatic complexing method, (D) using a compressor with variable stator nozzles, (E) carrying out the FTS reactions in a high-temperature multi-tubular reactor, (F) separating the FTS products using high-pressure fractional condensation, (G) separating CO2 from product streams for recycling through the RWGS reactor, and (H) using control methods to maintain temperatures of the reactors, electrolyzer, and condensers at optima that are functions of the flow rate. The RFTS process may also include heat engines, a refrigeration cycle utilizing compressed oxygen, and a dual-source organic Rankine cycle. | 2010-11-04 |
20100280136 | INTEGRATED MICROCHANNEL SYNTHESIS AND SEPARATION - A process for carrying out at least two unit operations in series, the process comprising the step of: (a) directing a feed stream into an integrated assembly which comprises a first microchannel unit operation upon at least one chemical of the feed stream to generate a distributed output stream that exits the first microchannel unit operation in a first set of discrete microchannels isolating flow through the discrete microchannels; and (b) directing the distributed output stream of the first microchannel unit operation into a second microchannel unit operation as a distributed input stream, to continue isolating flow between the first set of discrete microchannels, and conducting at least one operation upon at least one chemical of the input stream to generate a product stream that exits the second microchannel unit operation, where the first microchannel unit operation and the second unit operation share a housing. | 2010-11-04 |
20100280137 | METHOD AND APPARATUS FOR PRODUCING SYNTHESIS GAS FROM BIOMASS - The invention relates to a method and apparatus for producing synthesis gas ( | 2010-11-04 |
20100280138 | METHOD OF ACTIVATING BORON NITRIDE - A method of activating boron nitride comprises exposing the boron nitride to a fluid enabling —OH hydroxyl radicals and/or H | 2010-11-04 |
20100280139 | Sprayable elastomeric polyurethane foam and process for its production - The present invention relates to a sprayable elastomeric polyurethane foam made from the reaction product of at least one isocyanate, at least one isocyanate-reactive component and water, optionally in the presence of at least one of blowing agents, surfactants, cross-linking agents, extending agents, pigments, flame retardants, catalysts and fillers, wherein the sprayable elastomeric polyurethane foam has a free rise density of from about 5 lb/ft | 2010-11-04 |
20100280140 | Thermally Insulating Isocyanate-Based Foams - Propylene oxide, ethylene oxide, or a propylene oxide/ethylene oxide mixture are reacted with 1,2-phenylene diamine to form adducts having hydroxyl and amino groups. The 1,2-phenylene diamine adducts are useful in making rigid polyurethane foams, especially foams for pour-in-place applications, where they give a good combination of low k-factor and short demold times. The polyols also have unexpectedly low viscosities. | 2010-11-04 |
20100280141 | COMPOSITIONS AND USE OF CIS-1,1,1,4,4,4-HEXAFLUORO-2-BUTENE FOAM-FORMING COMPOSITION IN THE PREPARATION OF POLYISOCYANATE-BASED FORMS - A foam-forming composition is disclosed which includes both cis-1,1,1,4,4,4-hexafluoro-2-butene and a poorly compatible active hydrogen-containing compound having two or more active hydrogens. Also disclosed is a closed-cell polyurethane or polyisocyanurate polymer foam prepared from reaction of effective amounts of the foam-forming composition and a suitable polyisocyanate. Also disclosed is a process for producing a closed-cell polyurethane or polyisocyanurate polymer foam by reacting an effective amount of the foam-forming composition with a suitable polyisocyanate. | 2010-11-04 |
20100280142 | Shaped Information-Storage Material of Photopolymers and Methods for Making Same - A method for making shaped information-storage material of photo polymers includes mixing powdery azobisisobutyronitrile (AIBN) and powdery acenaphthenequinone (AQ) into liquid monomers of methyl methacrylate (MMA) and stirring a mixture of the AIBN, AQ, and MMA to form a solution. The azobisisobutyronitrile (AIBN) serves as a thermo polymerization initiator, and the acenaphthenequinone (AQ) serves as a photo polymerization initiator. The solution is filtered to remove the saturated photo polymerization initiator. Then, the filtered solution is poured into a shaping container and heated in the shaping container to make solid, shaped information-storage material of photo polymers. The shaping container is then opened to remove the shaped information-storage material of photo polymers. The shaped information-storage material of photo polymers includes two flat lateral sides. | 2010-11-04 |
20100280143 | SEALANT COMPOSITION - A sealant composition is provided. The sealant composition includes (a) an oligomer including an unsaturated mono-carboxylic acid modified bisphenol A epoxy resin and an unsaturated mono-carboxylic acid modified bisphenol F epoxy resin, wherein an equivalence ratio of the bisphenol A epoxy resin to the bisphenol F epoxy resin is 0.05:0.95 to 0.3:0.7, the bisphenol A epoxy resin has a melting point higher than 40° C. and the bisphenol F epoxy resin has a melting point lower than 40° C.; (b) an epoxy resin having at least two or more than two epoxy groups; and (c) a photoinitiator. | 2010-11-04 |
20100280144 | PHOTOCURABLE COATING COMPOSITION - Disclosed is a photocurable coating composition for an optical product, wherein the photocurable coating composition includes a (meth)acryloyl monomer, a (meth)acryloyl oligomer, an organic solvent and a diluted monomer, which provides heat resistance, storage stability and high light transmission while having a low viscosity sufficient to prevent discoloration of the optical product. | 2010-11-04 |
20100280145 | Ceramic Composite - The invention relates to a ceramic particulate and polymer composite having enhanced viscoelastic and rheological properties. | 2010-11-04 |